Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2026)

Bionano Genomics has disclosed Cash & Equivalents across 10 years of filings, most recently posting $3.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $3.4 million, down 6.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (down 6.21% YoY), and the FY2025 annual result was $3.0 million, down 67.4% from the prior year.
• Cash & Equivalents came in at $3.4 million for Q1 2026 at Bionano Genomics, up from $3.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $34.6 million in Q3 2023 to a low of $3.0 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $9.2 million (2024), against an average of $12.8 million.
• Across the five-year window, Cash & Equivalents plunged 93.36% in 2022 and soared 283.99% in 2024, its largest moves.
• Bionano Genomics' Cash & Equivalents stood at $5.1 million in 2022, then jumped by 252.54% to $17.9 million in 2023, then sank by 48.89% to $9.2 million in 2024, then slumped by 67.4% to $3.0 million in 2025, then climbed by 13.71% to $3.4 million in 2026.
• The last three Cash & Equivalents figures came in at $3.4 million (Q1 2026), $3.0 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.